The experimental analysis of this study showed that serum IL-6, IL-17 and VEGF levels are closely associated with the development, progression and invasion of breast cancer and can be used as monitoring indicators for clinical prognosis and efficacy assessment. Here, IL17A is linked to breast cancer.